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Background: Doravirine is a novel, nonnucleoside reverse
transcriptase inhibitor with demonstrated efficacy in treatment-
naive adults with HIV-1.
Methods: In this open-label, active-controlled, noninferiority trial,
adults with HIV-1 virologically suppressed for $6 months on 2
nucleoside reverse transcriptase inhibitors plus a boosted protease
inhibitor, boosted elvitegravir, or a non-nucleoside reverse transcrip-
tase inhibitor were randomized (2:1) to switch to once-daily, single-
tablet doravirine 100 mg with lamivudine 300 mg and tenofovir
disoproxil fumarate 300 mg (DOR/3TC/TDF) or to continue their
current therapy (Baseline Regimen) for 24 weeks. The primary
endpoint was the proportion of participants with HIV-1 RNA ,50
copies/mL (defined by the FDA Snapshot approach), with the
primary comparison between DOR/3TC/TDF at week 48 and
Baseline Regimen at week 24 and a secondary comparison between
the groups at week 24 (noninferiority margin, 28%).
Results: Six hundred seventy participants (447 DOR/3TC/TDF,
223 Baseline Regimen) were treated and included in the analyses. At
week 24, 93.7% on DOR/3TC/TDF vs 94.6% on Baseline Regimen
had HIV-1 RNA ,50 copies/mL [difference 20.9 (24.7 to 3.0)]. At
week 48, 90.8% on DOR/3TC/TDF had HIV-1 RNA ,50
copies/mL, demonstrating noninferiority vs Baseline Regimen at
week 24 [difference23.8 (27.9 to 0.3)]. In participants on ritonavir-
boosted protease inhibitor at entry, mean reductions in fasting LDL-
C and non-HDL-C at week 24 were significantly greater for DOR/
3TC/TDF vs Baseline Regimen (P , 0.0001). Adverse events
occurred in 68.9% on DOR/3TC/TDF and 52.5% on Baseline
Regimen by week 24, leading to treatment discontinuation in 2.5%
and 0.4%, respectively.
Conclusions: Switching to once-daily DOR/3TC/TDF is a gener-
ally well-tolerated option for maintaining viral suppression in
patients considering a change in therapy.
Registration: ClinicalTrials.gov NCT02397096.
Key Words: doravirine, HIV-1, treatment-experienced, noninfer-
iority
(J Acquir Immune Defic Syndr 2019;81:463–472)
Received for publication November 18, 2018; accepted February 25, 2019.
From the aDepartment of HIV Medicine, Royal Free Hospital, London, United Kingdom; bDivision of Infectious Diseases and Travel Medicine, Medstar
Georgetown University Hospital, Washington, DC; cUniversity of Paris Diderot, Hôpital Saint-Louis, Paris, France; dDepartment of Infectious Diseases, ASST
Fatebenefratelli Sacco Hospital, Milan, Italy; eSchool of Clinical Medicine, Faculty of Health Science, University of the Witwatersrand, Johannesburg, South
Africa; fFundación Huésped and Buenos Aires University, Buenos Aires, Argentina; gInfektiologikum, Center for Infectious Diseases, Frankfurt, Germany; hHIV
Unit, Infectious Diseases Service, Hospital Clinic, Barcelona, Spain; and iMerck & Co., Inc., Kenilworth, NJ.
Supported by Merck Sharp & Dohme Corp. (MSD), a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. Statistical support was provided by Hong Wan,
PhD, an employee of MSD. Medical writing, editorial assistance, and graphic support were provided by Kim Strohmaier, Carol Zecca, and Danielle
Mancaruso, employees of MSD.
Presented in part at IDWeek 2018; October 4, 2018; San Francisco, CA.
M.J. has received grants and consulting fees from Gilead and ViiV. P.K. is on Advisory Boards for ViiV, Janssen, Merck, and Theratechnologies; has received
grants from Merck, ViiV, Gilead, and Theratechnologies; and owns stock in Johnson & Johnson, Gilead, Merck, Pfizer, and GSK. J.-M.M. has received
grants from Gilead and consulting fees (Advisory Board) from Gilead and MSD. G.R. has received Advisory board and speaker fees from Janssen-Cilag,
Abbvie, Gilead Science, ViiV, MSD, and Angelini. P.C. is an Advisory Board member for MSD and ViiV and has received research grants from AbbVie,
MSD, and ViiV. J.M. has received honoraria, speakers’ fees, consultant fees or funds for research from MSD, Roche, Boehringer-Ingelheim, ViiV, Gilead,
Janssen, BMS, and Abbvie. Y.Z., C.M., S.K., P.S., G.J.H., C.H., and W.G. are current or former employees of MSD. The remaining authors have no conflicts
of interest to disclose.
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this
article on the journal’s Web site (www.jaids.com).
Correspondence to: Wayne Greaves, MD, Global Clinical Development, Merck Sharp & Dohme Corp., 126 E. Lincoln Avenue, RY34-A484, Rahway, NJ
07065-0900 (e-mail: wayne.greaves@merck.com).
Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open-access article distributed under the terms of the Creative Commons
Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly
cited. The work cannot be changed in any way or used commercially without permission from the journal.
J Acquir Immune Defic Syndr  Volume 81, Number 4, August 1, 2019 www.jaids.com | 463
INTRODUCTION
Viral suppression greatly reduces the risk of HIV-1
transmission, disease progression, and development of drug-
resistant HIV-1 strains.1 Among persons living with HIV and
receiving antiretroviral therapy (ART), only 62%–73%
achieve durable viral suppression.2–4 Adherence to ART is
among the key determinants of viral suppression; however,
only 53.6% of patients receiving ART report optimal
treatment adherence.5 Poor adherence may be related to
adverse drug effects, high pill burden, complex dosing
schedules, food requirements, and/or drug–drug interactions.
Current treatment guidelines recommend switching treatment-
experienced patients receiving complex or poorly tolerated
regimens to once-daily regimens to increase adherence,
improve quality of life, and reduce the likelihood of virologic
failure.6,7
Doravirine is a novel non-nucleoside reverse transcrip-
tase inhibitor (NNRTI) with the potential to be an important
option in the switch setting. Doravirine is active in vitro
against the most common NNRTI-resistant variants at con-
centrations achieved with once-daily dosing8,9 and has
a favorable resistance profile that is unique among NNRTIs.10
Doravirine can be taken with or without food11 and can be
coadministered with statins, oral contraceptives, and gastric
acid modifiers.12–14 In phase 3 trials in treatment-naive adults
with HIV-1 infection, doravirine 100 mg given with 2
nucleoside reverse transcriptase inhibitors (NRTIs) demon-
strated noninferior efficacy to ritonavir-boosted darunavir
with 2 NRTIs,15 and doravirine 100 mg in a single-tablet
regimen with lamivudine (3TC) 300 mg and tenofovir
disoproxil fumarate (TDF) 300 mg (DOR/3TC/TDF) demon-
strated noninferior efficacy to efavirenz/emtricitabine/TDF.16
In both trials, the doravirine regimen demonstrated a favorable
lipid profile and was generally well tolerated for up to 48
weeks. Doravirine also demonstrated a superior neuropsychi-




DRIVE-SHIFT (MK-1439A Protocol 024;
NCT02397096) is a phase 3, open-label, randomized,
active-controlled, noninferiority trial to evaluate switching
from a stable antiretroviral regimen to the once-daily, single-
tablet regimen DOR/3TC/TDF (see Supplemental Digital
Content, http://links.lww.com/QAI/B313). The trial was con-
ducted in conformance with ICH Good Clinical Practice
guidelines and applicable regulations regarding the protection
of human participants in biomedical research. The protocol
was approved by the independent ethics committee for each
study site, and all participants provided written informed
consent before any study procedures were performed.
Participants were enrolled at 122 hospitals and clinics
in Europe, North America, Latin America, and Asia. Adults
with HIV-1 and no history of virologic failure were eligible if
they had been virologically suppressed for $6 months on
a stable regimen consisting of a ritonavir- or cobicistat-
boosted protease inhibitor (PI) (atazanavir, darunavir, or
lopinavir), cobicistat-boosted elvitegravir, or an NNRTI
(efavirenz, nevirapine, or rilpivirine), each in combination
with 2 NRTIs. Participants receiving an NNRTI were on their
first antiretroviral regimen. For participants receiving
a boosted PI or boosted elvitegravir as their second anti-
retroviral regimen, HIV-1 RNA was ,40 copies/mL when
the first regimen was changed.
At screening, participants were required to have HIV-1
RNA ,40 copies/mL (Abbott RealTime Assay) and calcu-
lated creatinine clearance $50 mL/min (the Cockcroft–Gault
equation). Pretreatment HIV-1 genotyping was required for
participants receiving a boosted PI or boosted elvitegravir.
Exclusion criteria included resistance to doravirine, 3TC, or
TDF (see Supplemental Digital Content, http://links.lww.
com/QAI/B313), acute hepatitis, decompensated liver dis-
ease, liver cirrhosis, and use of systemic immunosuppressive
therapy or immune modulators within 30 days before study
treatment. Participants using lipid-lowering agents had to be
on a stable dose at enrollment.
Procedures
Randomization was determined by a computer-
generated allocation schedule and stratified by antiretroviral
class used in the baseline regimen (ritonavir-boosted PI vs
cobicistat-boosted PI vs either cobicistat-boosted elvitegravir
or an NNRTI) and by use of lipid-lowering therapy (yes/no)
for participants receiving ritonavir-boosted PI. Participants
were randomly assigned (2:1) to switch to DOR/3TC/TDF on
day 1 [Immediate Switch Group (ISG)] or to continue their
baseline regimen until week 24 and then switch to DOR/3TC/
TDF [Delayed Switch Group (DSG)]. DOR/3TC/TDF was
taken orally once daily at approximately the same time each
day and without regard to food. Each participant completed
a medication diary to document adherence to study therapy.
Changes in study therapy dosage were not allowed, although
study therapy could be interrupted for toxicity management.
Plasma HIV-1 RNA quantification was performed at all
visits by the central laboratory using the Abbott RealTime
HIV-1 assay. CD4+ T-cell count (absolute and percentage)
was determined at day 1 and weeks 12, 24, 36, and 48 by the
central laboratory using standard procedures.
Protocol-defined virologic failure (PDVF) was defined
as 2 consecutive measurements of HIV-1 RNA $50
copies/mL at least 1 week apart. Participants with confirmed
PDVF were discontinued from the trial, regardless of
adherence to study therapy. Viral drug resistance testing
was performed for participants with confirmed PDVF and for
those who discontinued early for other reasons, if their HIV-1
RNA was .400 copies/mL. For this analysis, postbaseline
genotypic viral resistance to DOR was defined as any of the
following mutations in the RT gene: A98G, L100I, K101E,
V106A, V106I, V106M, V108I, E138K, Y188L, G190A,
G190S, H221Y, P225H, F227C, F227L, F227V, M230I,
M230L, L234I, P236L, and Y318F. Postbaseline genotypic
and phenotypic resistance to 3TC and TDF was assessed by
Monogram Biosciences. Because the threshold for phenotypic
resistance to DOR has not yet been defined, a 2.5-fold change
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in IC50 vs wild-type virus was used as a broad assay
reproducibility threshold for potential phenotypic resistance
to DOR.
Primary and Secondary Outcome Measures
The primary efficacy outcome was the proportion of
participants with HIV-1 RNA ,50 copies/mL [as defined by
the Food and Drug Administration (FDA) Snapshot
approach], with the primary comparison at week 48 in the
DOR/3TC/TDF ISG vs week 24 in the Baseline Regimen
DSG. Because the longer assessment period for the DOR/
3TC/TDF ISG could lead to more nontreatment-related
dropouts (which are counted as treatment failures), an
additional efficacy comparison was performed based on
the week 24 assessments for both groups; this secondary
analysis was not included in the multiplicity strategy.
Other measurements for efficacy included the pro-
portion of participants with HIV-1 RNA$50 copies/mL, the
change from baseline in CD4+ T-cell counts, and the
development of viral resistance to study drugs. Safety
evaluations included the change from baseline in fasting
serum lipids (in participants whose regimen at screening was
a ritonavir-boosted PI), the incidence of adverse events
(AEs), and changes in laboratory safety tests (hematology
and chemistry). Laboratory values were graded according to
the Division of AIDS Table for Grading the Severity of
Adult and Pediatric AEs (Version 2.0, November 2014), and
an increase in grade from baseline was classified as
a laboratory abnormality.
Statistical Analysis
All randomized participants who received at least 1
dose of study therapy were included in the efficacy analyses,
which used the FDA Snapshot approach (all missing data
were treated as failures regardless of the reason). The
difference between treatment groups in the proportion of
participants with HIV-1 RNA ,50 copies/mL and the
associated 95% confidence interval (CI) were calculated
using the stratum-adjusted Mantel–Haenszel method. If the
lower bound of the 2-sided 95% CI was above 28 percentage
points, switching to DOR/3TC/TDF was considered non-
inferior to the baseline regimen. With 440 participants in the
DOR/3TC/TDF ISG and 220 in the Baseline Regimen DSG,
the study had 80% power to demonstrate the primary
hypothesis that switching to DOR/3TC/TDF through 48
weeks is noninferior to continuing the baseline regimen
through 24 weeks, at an overall 1-sided 2.5% alpha level
and assuming a true response rate of 85% for both
treatment groups.
To evaluate the consistency of the virologic response,
the difference between treatment groups (with a nominal,
unadjusted 95% CI) was calculated for subgroups based on
age (#median, .median), sex, geographic region, race,
ethnicity, hepatitis B or C coinfection, baseline CD4+ T-cell
count (,200 cells/mm3, $200 cells/mm3), antiretroviral class
in the baseline regimen, duration of previous antiretroviral
regimen ($12 months, ,12 months), and history of NNRTI-
class mutations (K103N, Y181C, or G190A in participants
receiving a boosted PI or elvitegravir at baseline).
The proportion of participants with HIV-1 RNA $50
copies/mL (as defined by the FDA Snapshot approach) was
also analyzed at both comparison time points, consistent with
recent FDA guidance on assessment of noninferiority in
antiretroviral switch trials.18 For this endpoint, a margin of 4
percentage points was used to assess the noninferiority of
a switch to DOR/3TC/TDF through 48 weeks compared with
continuation of the baseline regimen through 24 weeks.
For participants whose baseline regimen included
a ritonavir-boosted PI, the change in fasting lipids from
baseline to week 24 was analyzed using analysis of covari-
ance models adjusted by the baseline lipid level, use of lipid-
lowering therapy, and treatment group. If noninferiority for
the primary efficacy analysis was established, the hypotheses
on fasting low-density lipoprotein cholesterol (LDL-C) and
non-high-density lipoprotein cholesterol (non-HDL-C) were
tested sequentially. For participants with missing lipid data,
the last lipid observation after randomization was carried
forward. If lipid-lowering therapy was modified during the
study, the last lipid measurement before the modification was
carried forward.
RESULTS
Of 852 individuals screened between June 17, 2015
and February 10, 2017, 450 were randomized to the DOR/
3TC/TDF ISG and 223 to the Baseline Regimen DSG; 447
and 223 participants, respectively, received at least 1 dose of
study therapy and were included in the efficacy and safety
analyses. Demographics and baseline clinical characteristics
were balanced between the treatment groups (Table 1). The
study population was primarily men (84.5%) and white
(76.4%), with a median age of 43 years (range, 21–71). At
baseline, 70.4% of participants were receiving a boosted-PI
regimen, and the median CD4+ T-cell count was 628 cells/
mm3 (range, 82–1928). Sixty-one participants discontinued
study therapy by week 48: 40 (8.9%) from the ISG and 21
(9.4%) from the DSG. The most common reasons for early
discontinuation were AEs and withdrawal of consent
(Fig. 1).
Efficacy
At week 24, the proportion of participants with HIV-1
RNA ,50 copies/mL was 93.7% (419/447) in the DOR/
3TC/TDF ISG and 94.6% (211/223) in the Baseline
Regimen DSG (Fig. 2, Panel A). At week 48, HIV-1 RNA
,50 copies/mL was maintained in 90.8% (406/447) of the
DOR/3TC/TDF ISG (Fig. 2, Panel B), demonstrating that
switching to DOR/3TC/TDF is noninferior to continuing the
baseline regimen for 24 weeks [difference (95% CI), 23.8
(27.9 to 0.3)]. Of the 209 participants in the Baseline
Regimen DSG who switched to DOR/3TC/TDF at week 24,
198 (94.7%) had HIV-1 RNA ,50 copies/mL at week 48
(see Supplemental Digital Content, http://links.lww.com/
QAI/B313).
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Across subgroups defined by demographics and base-
line clinical characteristics, the antiretroviral efficacy of DOR/
3TC/TDF at week 24 was comparable to that of the baseline
regimen at week 24 (Fig. 3), consistent with the overall
results. Virologic response rates in the DOR/3TC/TDF ISG
were high regardless of the previous regimen: 93.0%, 100%,
and 94.3%, respectively, in participants switched from
boosted PIs, boosted elvitegravir, or NNRTIs. The efficacy
of DOR/3TC/TDF at week 48 was also comparable to the
baseline regimen at week 24 across demographics and
baseline clinical characteristics (see Supplemental Digital
Content, http://links.lww.com/QAI/B313).
Eleven participants in the DOR/3TC/TDF ISG had
NNRTI resistance mutations at baseline: 10 (90.9%) were
virologically suppressed at week 48, and 1 discontinued on
day 29 (due to protocol deviation) with HIV-1 RNA ,50
copies/mL. Thirteen participants in the Baseline Regimen DSG
had NNRTI resistance mutations at baseline; 12 of these
participants switched to DOR/3TC/TDF at week 24: 11
(91.7%) were virologically suppressed at week 48, and 1
discontinued on day 262 (due to noncompliance) with HIV-1
RNA ,50 copies/mL on day 195 (last available measurement).
The proportion of participants with HIV-1 RNA $50
copies/mL was 1.8% in both treatment groups at week 24 (Figs.
2) and 1.6% in the DOR/3TC/TDF ISG at week 48 (the primary
comparison time point), supporting the noninferiority of switching
to DOR/3TC/TDF [difference20.2 (22.5 to 2.1) vs the baseline
regimen at week 24]. The mean change from baseline in CD4+
T-cell count was minimal: +5 cells/mm3 in the DOR/3TC/TDF
ISG and +18 cells/mm3 in the Baseline Regimen DSG at week
24, and +14 cells/mm3 in the DOR/3TC/TDF ISG at week 48.
Eight participants met criteria for PDVF: 6 in the DOR/
3TC/TDF ISG, 1 in the Baseline Regimen DSG, and 1 in the
DSG after switching to DOR/3TC/TDF; none of these
participants had RT K103N, Y181C, and/or G190A muta-
tions at baseline. Three participants with PDVF (2 in the
DOR/3TC/TDF ISG and 1 in the Baseline Regimen DSG)
had samples with HIV-1 RNA .400 copies/mL available for
resistance testing. Neither ISG participant developed geno-
typic or phenotypic resistance to DOR, 3TC, or TDF. The
DSG participant (who was receiving ritonavir-boosted DRV,
FTC, and TDF) showed genotypic and phenotypic resistance
to 3TC and FTC (conferred through RT M184M/I) at week
12. Viral drug resistance testing was also performed for 3
participants (1 in the DOR/3TC/TDF ISG and 2 in the
Baseline Regimen DSG) who discontinued early without
PDVF. None of these participants developed genotypic or
phenotypic resistance to any component of the study therapy.
Safety and Tolerability
During weeks 0–24, AEs were reported by 68.9% of the
DOR/3TC/TDF ISG and 52.5% of the Baseline Regimen
DSG. In both groups, the majority of participants with AEs
rated the maximum intensity as mild (64.3% and 59.0%,
respectively). The most frequently reported AEs were naso-
pharyngitis and headache (Table 2). AEs that were considered
drug-related were reported during weeks 0–24 in 19.5% of the
DOR/3TC/TDF ISG and 2.2% of the Baseline Regimen DSG;
none of the specific drug-related AEs occurred in $2% of
either group. Among participants in the DSG who switched to
DOR/3TC/TDF at week 24, the AE profile during weeks
24–48 was similar to that reported for the DOR/3TC/TDF
ISG during weeks 0–24 (Table 2).
Rates of serious AEs were low in both treatment groups
during weeks 0–24 and during weeks 24–48 (Table 2). A total





Age (yrs), median (range) 43 (21–71) 42 (22–71)
Male, n (%) 372 (83.2) 194 (87.0)
Race/ethnicity, n (%)
White 344 (77.0) 168 (75.3)
Black or African American 56 (12.5) 34 (15.2)
Asian 17 (3.8) 8 (3.6)
Other race* 30 (6.7) 13 (5.8)
Hispanic or Latino ethnicity 99 (22.1) 45 (20.2)
Region, n (%)
Asia/Pacific 19 (4.3) 12 (5.4)
Europe 268 (60.0) 137 (61.4)
Latin America 49 (11.0) 24 (10.8)
North America 111 (24.8) 50 (22.4)
CD4+ T-Cell count
Median (range), cells/mm3 633 (82–1928) 625 (140–1687)
,200 cells/mm3, n (%) 13 (2.9) 4 (1.8)
$200 cells/mm3, n (%) 426 (95.3) 216 (96.9)
Previous ART
regimen, n (%)
Boosted PI 316 (70.7) 156 (70.0)
Darunavir 166 (37.1) 82 (36.8)
Atazanavir 96 (21.5) 43 (19.3)
Lopinavir 54 (12.1) 31 (13.9)
Cobicistat-boosted elvitegravir 25 (5.6) 12 (5.4)
NNRTI 106 (23.7) 55 (24.7)
Efavirenz 78 (17.4) 36 (16.1)
Nevirapine 17 (3.8) 12 (5.4)
Rilpivirine 11 (2.5) 7 (3.1)
Coadministered NRTIs, n (%)
TDF/FTC 330 (73.8) 154 (69.1)
TAF/FTC 22 (4.9) 11 (4.9)
TDF/3TC 10 (2.2) 10 (4.5)
ABC/3TC 61 (13.6) 28 (12.6)
ZDV/3TC 23 (5.1) 19 (8.5)
Duration of previous regimen
Median (range), mo 48.4 (7–265) 50.5 (7–181)
$12 months, n (%) 421 (94.2) 211 (94.6)
RT K103N, Y181C, and/or
G190A†
11 (2.5) 13 (5.8)
History of AIDS, n (%) 80 (17.9) 35 (15.7)
Hepatitis B and/or C,‡ n (%) 14 (3.1) 9 (4.0)
*Other races include multiracial, American Indian, and Alaska Native.
†NNRTI mutations on pre-ART genotype in participants on a boosted PI or
elvitegravir regimen; number of participants with specific mutations by the treatment
group (ISG, DSG): K103N (7, 11), Y181C (2, 0), G190A (1, 1), K103N/Y181C (0, 1),
Y181C/G190A (1, 0).
‡Evidence of hepatitis B surface antigen or hepatitis C virus RNA.
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of 5 participants had serious AEs that were considered related
to DOR/3TC/TDF: depression, increased lipase (grade 4),
concurrent elevations in alanine aminotransferase (ALT)
(grade 3) and aspartate aminotransferase (AST) (grade 2),
concurrent elevations in amylase and lipase (both grade 4),
and renal failure. The elevated ALT and AST resolved with
no change in therapy. In the other 4 participants, the study
drug was discontinued and the serious AEs resolved, except
for increased lipase in 1 participant (see Supplemental Digital
Content, http://links.lww.com/QAI/B313). No deaths were
reported during the study among randomized participants.
Rates of treatment discontinuation due to AEs were
low in both treatment groups during weeks 0–24 and during
weeks 24–48 (Table 2). These events were considered
related to DOR/3TC/TDF in 13 participants. The most
common AEs causing discontinuation were increased trans-
aminase levels (ALT, AST, or both; 4 participants) and
increased lipase (3 participants, none with pancreatitis).
Most AEs that led to discontinuation of DOR/3TC/TDF had
resolved or were resolving at the last study contact (see
Supplemental Digital Content, http://links.lww.com/QAI/
B313).
FIGURE 1. Trial profile. DOR/3TC/TDF, doravirine/lamivudine/tenofovir disoproxil fumarate. Baseline Regimen = 2 NRTIs with
a boosted PI, boosted elvitegravir, or an NNRTI. Percentages are based on the number of participants randomized (450 to ISG and
223 to DSG).
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In participants whose baseline regimen included a rito-
navir-boosted PI, the mean change in fasting LDL-C and non-
HDL-C from baseline to week 24 was significantly different
(P , 0.0001) between the treatment groups (Fig. 4). Fasting
cholesterol and fasting triglyceride levels were also sub-
stantially reduced among participants in the DOR/3TC/TDF
ISG (Fig. 4). The mean change in the total cholesterol:HDL-C
ratio was 20.44 in the DOR/3TC/TDF ISG and 20.57 in the
Baseline Regimen DSG. Lipid-lowering therapy was started
or changed (agent or dose) during the first 24 weeks of the
study in 1.3% of participants receiving DOR/3TC/TDF and
2.7% receiving the baseline regimen.
The incidence of grade 3 or 4 laboratory abnormalities
through week 24 was generally similar between the treatment
groups (Table 2). Five participants in the Baseline Regimen
DSG experienced a grade 3 increase in bilirubin; all 5 were
receiving ritonavir-boosted atazanavir. The laboratory profile
for the DSG after switching to DOR/3TC/TDF was similar to
that for the ISG during weeks 0–24. No participants in either
treatment group had laboratory values that met the criteria for
potential drug-induced liver injury (ALT or AST $3 · ULN
plus bilirubin $2 · ULN and alkaline phosphatase ,2
· ULN).
DISCUSSION
This randomized, open-label, phase 3 trial demon-
strated the efficacy and safety of switching from a stable
antiretroviral regimen to a single-tablet, fixed-dose regimen of
DOR/3TC/TDF in virologically suppressed adults with HIV-
FIGURE 2. Virologic outcomes (the FDA Snapshot approach). DOR/3TC/TDF, doravirine/lamivudine/tenofovir disoproxil fuma-
rate. Baseline Regimen = 2 NRTIs with a boosted PI, boosted elvitegravir, or an NNRTI.
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FIGURE 3. Proportion of participants with HIV-1 RNA ,50 copies/mL at week 24 (the FDA Snapshot approach) by prognostic
factors (A) and demographic factors (B).
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1 infection. Participants who received DOR/3TC/TDF for up
to 48 weeks showed high rates of virologic suppression with
low rates of virologic failure and discontinuation related to
AEs. An open-label study design was chosen to reduce dosing
complexity and to allow for evaluation of the acceptability of
a single-tablet regimen. Because participants had been
virologically suppressed for at least 6 months before enroll-
ment, a treatment duration of 48 weeks after switching was
considered important for evaluating the safety and tolerability
of DOR/3TC/TDF and its durability in maintaining viral
suppression. Because participants randomized to continue
their baseline regimen might not be willing to wait 48 weeks
before switching, this group was designated to switch at week
24. Thus, the primary efficacy analysis compared week 48 for
DOR/3TC/TDF with week 24 for the baseline regimen. A
secondary comparison was performed at week 24 for both
treatment groups to assess the virologic response at the same
duration of follow-up for both regimens.
Based on the proportion of participants with HIV-1
RNA ,50 copies/mL at week 24, switching to DOR/3TC/
TDF was comparable with continuation of the baseline
regimen (93.7% vs 94.6%). After an additional 24 weeks,
virologic suppression was maintained in 90.8% of partici-
pants receiving DOR/3TC/TDF, demonstrating the noninfe-
rior efficacy of DOR/3TC/TDF at week 48 compared with the
baseline regimen at week 24. The difference in response rates
for the primary comparison was mainly due to missing data
for nonvirologic reasons (7.6% vs 3.6%), including discon-
tinuations due to AEs. This imbalance reflects, in part, the
opportunity for additional events to occur in the DOR/3TC/
TDF ISG because of the longer evaluation period (48 weeks).
After this trial began, the recommended primary
endpoint in FDA guidance for HIV switch trials18 was
changed to HIV-1 RNA $50 copies/mL, which was a sec-
ondary endpoint in this trial. Switching to DOR/3TC/TDF
was comparable with continuation of the baseline regimen
with respect to this endpoint: 1.8% of both groups had HIV-1
RNA $50 copies/mL at week 24, as did 1.6% of the DOR/
3TC/TDF ISG at week 48.
The results for both virologic suppression and virologic
rebound in this trial are similar to the week 48 results of other
open-label switch trials, such as the STRIIVING study of
TABLE 2. AEs and Laboratory Abnormalities
No. (%) of participants with:
ISG Week 0–24
DOR/3TC/TDF (N = 447)
DSG Week 0–24 Baseline
Regimen (N = 223)
DSG Week 24–48
DOR/3TC/TDF (N = 209)
ISG Week 24–48
DOR/3TC/TDF (N = 427)
Any AE 308 (68.9) 117 (52.5) 126 (60.3) 253 (59.3)
Drug-related* AE 87 (19.5) 5 (2.2) 29 (13.9) 24 (5.6)
Serious AE 13 (2.9) 8 (3.6) 4 (1.9) 10 (2.3)
Serious drug-related AE 2 (0.4) 0 (0.0) 1 (0.5) 2 (0.5)
AE resulting in discontinuation† 11 (2.5) 1 (0.4) 4 (1.9) 6 (1.4)
Drug-related AE resulting in
discontinuation†
7 (1.6) 0 (0.0) 4 (1.9) 4 (0.9)
Death 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Most common AEs
(incidence $5% in any group)
Nasopharyngitis 33 (7.4) 12 (5.4) 9 (4.3) 19 (4.4)
Headache 29 (6.5) 5 (2.2) 14 (6.7) 12 (2.8)
Most common drug-related AEs
(incidence $2% in any group)
Headache 7 (1.6) 1 (0.4) 5 (2.4) 0 (0.0)
Most common grade 3 or 4
laboratory abnormalities,
(incidence $1% in any group)
LDL cholesterol mg/dL, grade 3 0/372 (0.0) 3/184 (1.6) 0/176 (0.0) 1/357 (0.3)
Total cholesterol mg/dL, grade 3 0/391 (0.0) 2/197 (1.0) 0/184 (0.0) 0/377 (0.0)
Triglycerides mg/dL, grade 3 1/391 (0.3) 2/197 (1.0) 1/184 (0.5) 1/377 (0.3)
Glucose mg/dL, grade 3 1/395 (0.3) 2/197 (1.0) 0/184 (0.0) 0/378 (0.0)
Total bilirubin mg/dL, grade 3 0/444 (0.0) 5/221 (2.3) 0/208 (0.0) 0/424 (0.0)
Alanine aminotransferase IU/L,
grade 4
0/444 (0.0) 0/221 (0.0) 2/208 (1.0) 0/424 (0.0)
Lipase IU/L, grade 3 4/444 (0.9) 1/221 (0.5) 2/208 (1.0) 5/424 (1.2)
Creatine kinase IU/L, grade 3 3/444 (0.7) 3/221 (1.4) 0/208 (0.0) 0/424 (0.0)
The DSG continued their baseline regimen until time of switch to DOR/3TC/TDF (week 24). Baseline Regimen = ritonavir or cobicistat-boosted PI, or cobicistat-boosted
elvitegravir, or NNRTI, each administered with 2 NRTIs.
*Determined by the investigator to be related to study therapy.
†Two participants in the ISG are counted in weeks 0–24 and in weeks 24–48 because their discontinuation was the result of AEs that occurred in both periods (see Supplemental
Digital Content, http://links.lww.com/QAI/B313).
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abacavir/dolutegravir/lamivudine (83% with HIV-1 RNA
,50 copies/mL, ,1% with HIV-1 RNA $50 copies/mL),19
the EMERALD study of darunavir/cobicistat/emtricitabine/
tenofovir alafenamide (94.9% and 2.5%, respectively),20 and
the GS-US-380-1878 study of bictegravir/emtricitabine/
tenofovir alafenamide (92% and 2%, respectively).21
Very few participants (7/676) met the criteria for PDVF
after switching to DOR/3TC/TDF, and no viral resistance to
DOR was identified in the participants whose samples could
be tested. At study entry, 24 participants had virus with
NNRTI resistance mutations K103N, Y181C, and/or G190A;
of the 23 who switched to DOR/3TC/TDF, 21 remained
suppressed through week 48 and 2 discontinued early for
other reasons but were suppressed at their last study visit.
These clinical findings are consistent with the in vitro activity
of doravirine.
Switching to DOR/3TC/TDF demonstrated a superior
lipid profile compared with continuation of a ritonavir-
boosted PI-based regimen, with a statistically significant
difference between the treatment groups for both LDL-C
and non-HDL-C at week 24 (P , 0.0001). Previous studies
have shown that DOR is lipid neutral in treatment-naive
adults,15,16 whereas boosted PIs are associated with increased
lipid levels.22 This trial shows that switching from a boosted
PI to DOR/3TC/TDF improves lipid profiles.
DOR/3TC/TDF was generally well tolerated for up to
48 weeks, with no deaths and low rates of serious AEs and
discontinuation due to AEs. Compared with participants who
continued their baseline regimen, participants who switched
to DOR/3TC/TDF had higher rates of any AE (68.9% vs
52.5%) and of treatment-related AEs (19.5% vs 2.2%) at
week 24. The higher AE rates in the DOR/3TC/TDF group
are not unexpected because these participants switched to
a new treatment regimen, whereas participants in the Baseline
Regimen group continued on the same therapy they had
received for at least 6 months before entering this trial. In
addition, because the participants were not blinded to whether
they received the new regimen, ascertainment bias may have
contributed to the difference in AE rates. Other antiretroviral
switch studies have also found that participants who switched
to a new regimen reported more drug-related AEs than those
who continued their previous regimen, particularly when the
trial was not blinded.19–21,23
Despite the high incidence of AEs reported, only 2% of
participants (13/656) discontinued DOR/3TC/TDF because of
AEs that were considered treatment related. Overall, the
safety profile of DOR/3TC/TDF in treatment-experienced
participants who switched to this regimen was consistent with
the safety profile observed in the treatment-naive trials,
DRIVE-FORWARD and DRIVE-AHEAD,15,16 although the
rate of drug-related AEs in the current trial (19.5%) was lower
than in treatment-naive participants (31%).
In summary, switching to DOR/3TC/TDF was non-
inferior to continuation of the previous regimen in virolog-
ically suppressed adults with HIV-1, with high rates of
virologic suppression and low rates of virologic rebound.
No resistance to DOR developed in either treatment group.
DOR/3TC/TDF demonstrated a favorable safety profile over
48 weeks of treatment, and switching to DOR/3TC/TDF was
associated with a favorable lipid profile compared with
a boosted-PI regimen. These results show that switching to
once-daily DOR/3TC/TDF is an effective and generally well-
tolerated option for maintaining viral suppression in patients
considering a change in therapy.
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